Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDT-301 repRNA Vaccine in Healthy Adults
NCT04844268Phase 1Unknown
- Sponsor
- SENAI CIMATEC
- Start
- Jan 2022
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HDT-301 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by SENAI CIMATEC. Primary endpoints: Safety and tolerability of VACCINE RNA MCTI CIMATEC HDT at 84 days and Reactogenicity of VACCINE RNA MCTI CIMATEC HDT at 7 days. Status: unknown.
02
Drugs
HDT-301
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04844268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844268.